Evidence map›Paper›PMID 29665947›Full record

ReviewThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2018

The burden of multidrug-resistant tuberculosis in children.

H E Jenkins, C M Yuen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 101 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Bedaquiline for multidrug-resistant TB in paediatric patients.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Treatment of pre-extensively drug-resistant tuberculosis in a 4-month-old infant using a regimen of bedaquiline, delamanid, and contezolid.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

H E JenkinsDepartment of Biostatistics, Boston University School of Public Health, Boston.
C M YuenDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Boston University · USBrigham and Women's Hospital · US

Funding

Understanding spatial heterogeneity of drug resistant tuberculosisK01AI102944 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI JENKINS, HELEN E. · 2013 to 2017
$627k
NIAID NIH HHS K01 AI102944
6 · The paper itself

Abstract

backgroundChildhood tuberculosis (TB) has historically been neglected, although in recent years there has been increased focus on this problem. In particular, there have been two efforts to estimate the burden of pediatric multidrug-resistant TB (MDR-TB).

methodsWe review current estimates of the global incidence of pediatric MDR-TB disease. We then combine pediatric MDR-TB treatment data from the World Health Organization and recently published case fatality ratio estimates for children with TB to produce mortality estimates for children with MDR-TB. Finally, we combine treatment data and estimates of household size and disease risk to estimate how many children could be treated for probable or confirmed MDR-TB by carrying out household contact investigations around adult MDR-TB patients.

resultsBetween 25 000 and 32 000 children develop MDR-TB disease annually, accounting for around 3% of all pediatric TB cases. Only 3-4% of these children are likely to receive MDR-TB treatment. We estimate that around 21% of children who develop MDR-TB disease will die. Carrying out household contact investigations around adult MDR-TB patients could find an estimated 12 times as many pediatric MDR-TB cases as are currently being identified. DISCUSSION: The diagnosis and treatment of children with MDR-TB needs to be prioritized by TB programs.

Indexed as

Global Burden of DiseaseAntitubercular AgentsChildHumansIncidenceTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID29665947
PMCPMC5975247
OpenAlexW2802350967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.